Skip to content

Ohr Pharmaceuticals wins fast-track designation from FDA for squalamine topical treatment of wet age-related macular degeneration

Ohr Pharmaceuticals (OTCBB:OHRP), a US pharmaceutical company based in New York has announced the awarding of fast track designation by the FDA for its squalamine eye drops, an experimental anti-angiogenic treatment for wet age-related macular degeneration. In a key biodistribution and safety study the company was able to demonstrate that topical application of the eye drops had rapid uptake to the posterior sclera/choroid tissues with slow tissue clearance and that concentrations of the drug remained above anti-angiogenic threshold levels between dosings. In addition, the company reported no signs of ocular adverse findings and only negligible systemic uptake. If subsequent clinical studies support comparable efficacy with current standard of care treatments then the drug may well have a significant impact in the wet AMD market.